Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

LONDON, UK, 11 February 2025, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and ...

Renalys Pharma, Inc., a privately held late-stage clinical biopharmaceutical company based in Japan, announced that it has completed patient enrollment and reached the target number of cases for its ...

TOKYO, Jan. 30, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The registrational Phase III study ...